Association between response to primary treatments and MGMT status in glioblastoma

Enrico Franceschi, Alicia Tosoni, Eugenio Pozzati, Alba A. Brandes

Research output: Contribution to journalArticlepeer-review


The median overall survival and, more importantly, the 2-year survival rate of patients with newly diagnosed glioblastoma are increased by the administration of combined temozolomide and radiotherapy, which has recently become the new-standard of treatment in patients with a histological confirmation of diagnosis. Moreover, the assessment of O6-methylguanine-DNA methyltransferase gene promoter methylation has clarified the impact of this approach, and improved upon the interpretation of doubtful cases after concurrent radiotherapy/ temozolomicle treatment. Therefore, future strategies in the treatment of glioblastoma patients will include stratification for MGMT methylation status, and various approaches based on epigenetic features are currently under investigation.

Original languageEnglish
Pages (from-to)1781-1786
Number of pages6
JournalExpert Review of Anticancer Therapy
Issue number11
Publication statusPublished - 2008


  • Glioblastoma
  • MGMT
  • Radiotherapy
  • Temozolomide

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Association between response to primary treatments and MGMT status in glioblastoma'. Together they form a unique fingerprint.

Cite this